China’s Investigator-Initiated Pathway (IIT) could help accelerated biotech development, but it needs to be approach judiciously.

The IIT model allows some early cell and gene therapy studies to begin through hospitals and academic investigators, rather than always starting through the full drug-registration pathway.

The Upside

– Faster human PoC
– Quicker enrollment
– More clinician-led exploratio
– Earlier human data, especially where animal models are unreliable.

Great for rare diseases, oncology, cell therapy, and gene editing.

Recent Undisclosed Deaths and Risks

For high-risk therapies, speed has to come with near-IND standards:
– Strong manufacturing controls 
– Relevant toxicology and clear dose rationale 
– Independent safety oversight and informed consent
– Predefined stopping rules 
– Rapid adverse-event reporting

China’ Newer Order 818 (Sep 2025) and Guardrails

– Will those guardrails preserve the speed that makes IITs attractive?
– Will they build enough transparency to sustain trust?

Biotech does need faster clinical learning. But increased speed only creates value when the data are credible, interpretable, and ethically generated.

𝗦𝗼𝘂𝗿𝗰𝗲𝘀
– FierceBiotech – https://www.fiercebiotech.com/biotech/after-2-undisclosed-gene-therapy-deaths-can-china-iit-alternative-regulatory-path-still-be
– China State Council Order 118 (Sep 2025) https://cisema.com/news/china-biomedical-tech-principles
– FDA IND Overview https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application